DealerSocket closes acquisition of Auto/Mate to offer innovative DMS

DealerSocket closes acquisition of Auto/Mate to offer innovative DMS

Date: 2020-02-11 By Mateen Dalal

DealerSocket, a customer relationship management solutions provider, has recently completed the acquisition of DMS provider Auto/Mate to offer an all-in-one innovative software for their dealerships. Auto/Mate is a leadi....

EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G

The European Union and the United States are likely to partner to counter the increasing dominance of Chinese tech giant, Huawei Technologies on next generation 5G telecommunications technology. However, this partnership will reportedly onl....

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around ....

Pyxus inks agreement with Turning Point to initiate PMTA submission

Pyxus International, Inc., one of the leading value-added agricultural companies in the world, has reportedly collaborated with Turning Point Brands, a leading company in OTP (Other Tobacco Products) and adult consumer alternatives. Source....

Alkahest doses first patient in Phase 2 trial for Parkinson’s therapy

Alkahest will initiate Phase 2 trial for AKST4290, an inhibitor to treat Parkinson’s disease The firm has been partly funded by The Michael J. Fox Foundation for the research Alkahest, Inc., a biotech firm involved in the develop....

Moleculin announces US Phase 1 AML trial completion for Annamycin

Moleculin Biotech, Inc., a preclinical pharmaceutical company and developer of anti-cancer drug candidates, has recently announced the completion of its US Phase 1 trial. The open label, single arm clinical trial met its primary objective t....

AntiCancer to test its methioninase as a new treatment for coronavirus

The threat of coronavirus needs to be addressed as early as possible, particularly since there are no particular treatments or vaccines currently available for patients suffering from coronavirus globally. As the count of patients infected ....